SQZ Biotechnologies Company (OTCMKTS:SQZB – Get Free Report) was the target of a significant decline in short interest during the month of September. As of September 30th, there was short interest totaling 6,479 shares, a decline of 65.7% from the September 15th total of 18,887 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 4,824 shares, the days-to-cover ratio is currently 1.3 days.
SQZ Biotechnologies Stock Performance
SQZB opened at $0.02 on Wednesday. SQZ Biotechnologies has a 52-week low of $0.02 and a 52-week high of $0.05. The business’s 50-day simple moving average is $0.02 and its 200 day simple moving average is $0.02.
SQZ Biotechnologies Company Profile
SQZ Biotechnologies Co was a biotechnology company that developed cell therapies using its proprietary Cell Squeeze platform. The technology was designed to deliver biological materials, including proteins, nucleic acids and other therapeutic agents, directly into cells without relying on conventional viral vectors.
The company focused primarily on oncology and immune-mediated diseases. Its research programs included engineered immune-cell therapies intended to recognize and attack cancer, as well as approaches designed to enhance the function of immune cells.
See Also
- Five stocks we like better than SQZ Biotechnologies
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
